SWOG clinical trial number
SWOG-9307
Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot
Activated
07/01/1993
Closed
06/01/1996
Research committees
Lung Cancer
Publication Information Expand/Collapse
1999
Treatment of poor prognosis extensive disease small cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - A Southwest Oncology Group clinical and pharmacokinetic study.
1997
Oral etoposide (VP) and oral cyclophosphamide (CP) for poor prognosis extensive disease (ED) small cell lung cancer (SCLC). A Southwest Oncology Group clinical and pharmacokinetic study.
1994
Extended oral etopside (E) and oral cyclophosphamide (C) for lung cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open